276 related articles for article (PubMed ID: 33318018)
1. Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and
Miesel L; Cushion MT; Ashbaugh A; Lopez SR; Ong V
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318018
[TBL] [Abstract][Full Text] [Related]
2. The Long-Acting Echinocandin, Rezafungin, Prevents Pneumocystis Pneumonia and Eliminates Pneumocystis from the Lungs in Prophylaxis and Murine Treatment Models.
Cushion MT; Ashbaugh A
J Fungi (Basel); 2021 Sep; 7(9):. PubMed ID: 34575785
[TBL] [Abstract][Full Text] [Related]
3. Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy.
Miesel L; Lin KY; Ong V
Pharmacol Res Perspect; 2019 Dec; 7(6):e00546. PubMed ID: 31763045
[TBL] [Abstract][Full Text] [Related]
4. Rezafungin: a novel antifungal for the treatment of invasive candidiasis.
Ham YY; Lewis JS; Thompson GR
Future Microbiol; 2021 Jan; 16(1):27-36. PubMed ID: 33438477
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020).
Carvalhaes CG; Klauer AL; Rhomberg PR; Pfaller MA; Castanheira M
J Clin Microbiol; 2022 Apr; 60(4):e0244921. PubMed ID: 35249367
[TBL] [Abstract][Full Text] [Related]
6. Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018).
Pfaller MA; Carvalhaes C; Messer SA; Rhomberg PR; Castanheira M
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015043
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections.
Rubino CM; Flanagan S
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0084221. PubMed ID: 34398673
[TBL] [Abstract][Full Text] [Related]
8. Determination of Pharmacodynamic Target Exposures for Rezafungin against Candida tropicalis and Candida dubliniensis in the Neutropenic Mouse Disseminated Candidiasis Model.
Lepak AJ; Zhao M; Andes DR
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31481440
[TBL] [Abstract][Full Text] [Related]
9. Metabolism, Excretion, and Mass Balance of [
Ong V; Wills S; Watson D; Sandison T; Flanagan S
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0139021. PubMed ID: 34662192
[TBL] [Abstract][Full Text] [Related]
10. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.
Thompson GR; Soriano A; Cornely OA; Kullberg BJ; Kollef M; Vazquez J; Honore PM; Bassetti M; Pullman J; Chayakulkeeree M; Poromanski I; Dignani C; Das AF; Sandison T; Pappas PG;
Lancet; 2023 Jan; 401(10370):49-59. PubMed ID: 36442484
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic Evaluation of Rezafungin (CD101) against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model.
Lepak AJ; Zhao M; Andes DR
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30181375
[TBL] [Abstract][Full Text] [Related]
12. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD; Lyseng-Williamson KA; Scott LJ
Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model.
Hager CL; Larkin EL; Long LA; Ghannoum MA
J Antimicrob Chemother; 2018 Aug; 73(8):2085-2088. PubMed ID: 29897469
[TBL] [Abstract][Full Text] [Related]
14. An evaluation of Rezafungin: the latest treatment option for adults with candidemia and invasive candidiasis.
Sharma D; Vazquez JA
Expert Opin Pharmacother; 2024 Mar; 25(4):339-347. PubMed ID: 38497379
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis.
Roepcke S; Passarell J; Walker H; Flanagan S
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0091623. PubMed ID: 38014945
[TBL] [Abstract][Full Text] [Related]
16. Common invasive fungal diseases: an overview of invasive candidiasis, aspergillosis, cryptococcosis, and Pneumocystis pneumonia.
Schmiedel Y; Zimmerli S
Swiss Med Wkly; 2016; 146():w14281. PubMed ID: 26901377
[TBL] [Abstract][Full Text] [Related]
17. Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata.
Bader JC; Lakota EA; Flanagan S; Ong V; Sandison T; Rubino CM; Bhavnani SM; Ambrose PG
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555634
[TBL] [Abstract][Full Text] [Related]
18. Rezafungin: First Approval.
Syed YY
Drugs; 2023 Jun; 83(9):833-840. PubMed ID: 37212966
[TBL] [Abstract][Full Text] [Related]
19. Management of invasive candidiasis: A focus on rezafungin, ibrexafungerp, and fosmanogepix.
August BA; Kale-Pradhan PB
Pharmacotherapy; 2024 Jun; 44(6):467-479. PubMed ID: 38721866
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice.
Abruzzo GK; Gill CJ; Flattery AM; Kong L; Leighton C; Smith JG; Pikounis VB; Bartizal K; Rosen H
Antimicrob Agents Chemother; 2000 Sep; 44(9):2310-8. PubMed ID: 10952573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
